Updated safety results from phase 3 lecanemab study in early Alzheimer’s diseaseLawrence S. Honig, Lynn D. Kramer, Marwan N. Sabbagh et al.|Alzheimer s Research & Therapy|2024Cited by 150
The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's diseaseJonathan H. Fox, Steven M. Hersch|Molecular Neurodegeneration|2010Cited by 96
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical TrialMichael Brownstein, Stephanie Lowenhaupt, Codrin Lungu et al.|Journal of Clinical Medicine|2020Cited by 32
LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s DiseaseVanita Chopra, Steven M. Hersch|Journal of Huntington s Disease|2016Cited by 31